Treatment of Tardive Dyskinesia With Bromocriptine

摘要: • Pathophysiologic theories postulate that tardive dyskinesia arises from the development of chemical denervation supersensitivity dopamine receptors produced by chronic long-term neuroleptic treatment. To test a receptor modification strategy, 16 patients with were assigned to treatment plus bromocriptine (a agonist) or placebo for 10 weeks in rising-dose design. Patients evaluated weekly during 10-week period and 8 after medication withdrawal. No significant effect was found response overall sample. When classified subtype, choreoathetoid symptoms exhibited only slight improvement active treatment, which persisted drug withdrawal; dystonic showed moderate dose dependent. The sustained administration substantial doses agonist did not produce adverse effects, including behavioral toxic effects. These results, although statistically significant, are clinical heuristic interest.